Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2014 14:49 ET | Source: Gentium S.p.A.

Gentium S.p.A. Announces Decision to Voluntarily Delist American Depositary Shares from The NASDAQ Global Market

VILLA GUARDIA (COMO), Italy, March 5, 2014 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT), a Jazz Pharmaceuticals company, today announced that it has notified the NASDAQ Stock Market of its...
December 19, 2013 16:47 ET | Source: Gentium S.p.A.

Jazz Pharmaceuticals and Gentium S.p.A. Announce Agreement for Jazz Pharmaceuticals to Acquire Gentium for $57.00 Per Share

Transaction would add a significant growth product in the European Union and Rest of World markets, Defitelio™ (defibrotide), a treatment for severe hepatic veno-occlusive disease in adults...
December 11, 2013 07:00 ET | Source: Gentium S.p.A.

Interim Results From Gentium's Treatment IND for Defibrotide and Additional Data on Defibrotide in the Prevention of Acute Graft Versus Host Disease (aGvHD) Presented at the American Society of Hematology Annual Meeting

VILLA GUARDIA (COMO), Italy, Dec. 11, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that additional data on Defibrotide were presented this week at the 55th...
November 26, 2013 07:00 ET | Source: Gentium S.p.A.

Data From Non HSCT VOD Patients Treated With Defibrotide and a Treatment IND Update to be Presented at the American Society of Hematology 2013 Annual Meeting

VILLA GUARDIA (COMO), Italy, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that an oral presentation and a poster on Defibrotide will be presented at...
November 19, 2013 07:00 ET | Source: Gentium S.p.A.

Gentium Receives EMA Orphan Drug Designation for Defibrotide for the Prevention of GvHD

VILLA GUARDIA, Italy, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Commission ("EC") has granted Orphan Drug Designation to...
November 14, 2013 07:00 ET | Source: Gentium S.p.A.

Defibrotide Granted Orphan Drug Status in Australia

VILLA GUARDIA (COMO), Italy, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) and Link Healthcare today announced that Defibrotide has been designated as an Orphan Drug for the Treatment...
November 12, 2013 07:00 ET | Source: Gentium S.p.A.

Gentium Announces Successful Completion of Defibrotide Phase 1 Study in Japan

VILLA GUARDIA (COMO), Italy, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the medical team from the Phase 1 Trial Unit of the Translational...
October 31, 2013 06:00 ET | Source: Gentium S.p.A.

Gentium Reports Third Quarter 2013 Financial Results

EU commission grants Gentium Marketing Authorization for Defitelio® (defibrotide) Defibrotide revenues up 41% and 72% to EUR 24.22 million (USD 32.71 million) and to EUR 9.96 million...
October 28, 2013 07:45 ET | Source: Gentium S.p.A.

Gentium to Report Third Quarter 2013 Financial Results

VILLA GUARDIA (COMO), Italy, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it will report its financial results for the third quarter 2013 on...
October 22, 2013 06:00 ET | Source: Gentium S.p.A.

Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)

VILLA GUARDIA, Italy, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Commission has granted a Marketing Authorization for...